Day: March 9, 2023

Fourth-Quarter 2022: Revenue of $8.4 million, a 17% increase over Q4 2021Full-Year 2022: Revenue of $30.5 million, a 17% increase over 2021 HOPEWELL JUNCTION, N.Y., March 09, 2023 (GLOBE NEWSWIRE) — eMagin Corporation, or the “Company,” (NYSE American: EMAN), a U.S.-based leader in the development, design and manufacture of Active Matrix OLED microdisplays for high-resolution, AR/VR and other near-eye imaging products, today announced results for its fourth quarter and full-year 2022. Fourth Quarter and Full-Year HighlightsFourth-quarter 2022 revenue of $8.4 million, a 17% increase over the fourth quarter of 2021 Full-year 2022 revenue of $30.5 million, a 17% increase over full-year 2021 Achieved positive EBITDA for the fourth quarter and the full year of 2022 As of December 31, 2022, strong backlog of open orders of $14.8 million,...

Year Over Year Revenues Track the Five Year Plan by Increasing 21% ($45 million) to $257 Million CUPERTINO, CA, March 09, 2023 (GLOBE NEWSWIRE) — via NewMediaWire –Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on below zero carbon intensity products, today announced its financial results for the three and twelve months ended December 31, 2022. “Revenues for 2022 increased 21% compared to 2021, largely due to price increases in ethanol feed co-products in the United States and demand from oil marketing companies in India,” said Todd Waltz, Chief Financial Officer of Aemetis.  “Revenues during 2022 increased to $257 million compared to $212 million during 2021. Capital expenditures for carbon intensity reduction projects were $49.5 million for 2022 as our engineering and construction...

CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) — Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the fiscal year ended December 31, 2022 and provided an update on recent business developments and Company progress. Blue Water Vaccines is a preclinical stage biotechnology company developing vaccines against multiple infectious diseases, including acute otitis media (“AOM”) and pneumonia from Streptococcus pneumoniae colonization, influenza, norovirus, rotavirus, monkeypox, Marburg virus disease and Chlamydia. “In addition to our successful initial public offering and raising subsequent capital to extend our runway, we made significant corporate progress and further developed our vaccine candidates throughout the year,” said Joseph Hernandez, Chairman and Chief Executive...

On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in the second half of 2023 FDA clearance of IND application for BDTX-4933 in the first quarter of 2023, a brain-penetrant RAF MasterKey inhibitor for the treatment of all-class RAF and RAS mutant tumors; initiation of Phase 1 clinical trial expected in the first half of 2023 Presented new preclinical data demonstrating the potential of MasterKey programs BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium Cash, cash equivalents, and investments of $122.8 million as of December 31, 2022; expected to be sufficient to fund operations into the third quarter of 2024CAMBRIDGE, Mass. and NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage...

First Quarter Fiscal 2023 Financial Highlights(All comparisons are year-over-year unless otherwise noted)Revenues of $37.1 million compared to $31.8 million Gross profit of $5.2 million compared to a gross loss of $(2.9) million Loss from operations of $(22.5) million compared to $(44.8) million Net loss per share was $(0.05) compared to $(0.11)DANBURY, Conn., March 09, 2023 (GLOBE NEWSWIRE) — FuelCell Energy, Inc. (Nasdaq: FCEL) — a global leader in decarbonizing power and producing hydrogen through its proprietary, state-of-the-art fuel cell platforms to enable a world empowered by clean energy — today reported financial results for its first quarter ended January 31, 2023. “For the first quarter of fiscal year 2023, we reported strong revenue growth, up 17% compared to the comparable prior year quarter,” said...